Infographic

Summary of results for people diagnosed with exocrine pancreatic cancer (ICD-10 code C25.0) in England (2021-22) and in Wales (2022-23).



Diagnosis and staging

diagnoses of pancreatic cancer in England in 2021-22

England 51% Men 50% Women

74


years

diagnoses of pancreatic cancer in Wales in 2022-23

Wales **50%** Men **50%** Women

Median age at diagnosis (England and Wales)

Stage at diagnosis*



Work up and waiting times




of people had a record of an Multi-Disciplinary Team discussion in England.

Diagnosis

Median waiting times** (IQR***)








Treatment

Percentage of people receiving any form of diseasetargeted treatment





65 % (England) and 60% (Wales) of people with performance status 0-2 (stage 1-3) received any form of disease-targeted treatment

Supportive care




of people diagnosed during 2020-21 in England were prescribed PERT in primary care. Note: more likely to be prescribed PERT if receiving disease-targeted treatment (84% vs 38%)



of people with new diagnoses of pancreatic cancer were seen by a Clinical Nurse Specialist in England ****

Survival

Percentage of people who survived for 30 days or 1 year after diagnosis in England and Wales.



^{*} Based on people with complete staging information available

^{**} The figure is based on people diagnosed after GP referral in both England and Wales

^{***} Interquartile range - a measure of the spread of the results. It demonstrates the difference between the first quartile (lower 25%) and the third quartile (upper 25%) of results.

^{****} Information missing for 48% of people